BR112014013276A2 - vetores hvt recombinantes expressando antígenos de patógenos aviários e usos dos mesmos - Google Patents

vetores hvt recombinantes expressando antígenos de patógenos aviários e usos dos mesmos

Info

Publication number
BR112014013276A2
BR112014013276A2 BR112014013276-3A BR112014013276A BR112014013276A2 BR 112014013276 A2 BR112014013276 A2 BR 112014013276A2 BR 112014013276 A BR112014013276 A BR 112014013276A BR 112014013276 A2 BR112014013276 A2 BR 112014013276A2
Authority
BR
Brazil
Prior art keywords
recombinant
vectors
recombinant hvt
vectors expressing
hvt vectors
Prior art date
Application number
BR112014013276-3A
Other languages
English (en)
Other versions
BR112014013276B1 (pt
Inventor
Bublot Michel
Mebatsion Teshome
Pritchard Joyce
Linz Perry
Original Assignee
Merial Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47358292&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014013276(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merial Limited filed Critical Merial Limited
Publication of BR112014013276A2 publication Critical patent/BR112014013276A2/pt
Publication of BR112014013276B1 publication Critical patent/BR112014013276B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/869—Herpesviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/17—Newcastle disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/255—Marek's disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/03—Herpetoviridae, e.g. pseudorabies virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
    • C07K14/125—Newcastle disease virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/14—Reoviridae, e.g. rotavirus, bluetongue virus, Colorado tick fever virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/00034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/10011—Birnaviridae
    • C12N2720/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

resumo da patente de invenção para: “vetores hvt recombinantes expressando antígenos de patógenos aviários e usos dos mesmos”. a presente invenção fornece vetores de herpesvírus de peru recombinates (hvt) que contêm e expressam antígenos de agentes patogênicos de aves, composições que compreendem os vetores de hvt recombinantes, vacinas polivalentes compreendendo os vetores de hvt recombinantes e um ou mais vírus do tipo selvagem ou vetores recombinantes. a presente invenção fornece ainda métodos de vacinação contra uma variedade de patógenos aviários e um método de produzir os vetores de hvt recombinantes
BR112014013276-3A 2011-11-30 2012-11-29 Vetores hvt recombinantes expressando antígenos de patógenos aviários e usos dos mesmos BR112014013276B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161564877P 2011-11-30 2011-11-30
US61/564,877 2011-11-30
US201261694957P 2012-08-30 2012-08-30
US61/694,957 2012-08-30
PCT/US2012/067135 WO2013082327A1 (en) 2011-11-30 2012-11-29 Recombinant hvt vectors expressing antigens of avian pathogens and uses thereof

Publications (2)

Publication Number Publication Date
BR112014013276A2 true BR112014013276A2 (pt) 2018-05-15
BR112014013276B1 BR112014013276B1 (pt) 2021-07-27

Family

ID=47358292

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014013276-3A BR112014013276B1 (pt) 2011-11-30 2012-11-29 Vetores hvt recombinantes expressando antígenos de patógenos aviários e usos dos mesmos

Country Status (28)

Country Link
EP (7) EP3578199A1 (pt)
JP (1) JP6149301B2 (pt)
KR (1) KR102013135B1 (pt)
CN (3) CN104159604B (pt)
AR (2) AR090401A1 (pt)
BR (1) BR112014013276B1 (pt)
CA (1) CA2857025C (pt)
CO (1) CO7061033A2 (pt)
CY (3) CY1121528T1 (pt)
DK (3) DK2785373T3 (pt)
ES (3) ES2785045T3 (pt)
HK (4) HK1247832A1 (pt)
HR (3) HRP20190525T4 (pt)
HU (3) HUE047724T2 (pt)
IN (1) IN2014CN04833A (pt)
LT (3) LT2785374T (pt)
ME (1) ME03433B (pt)
MX (2) MX361893B (pt)
PE (1) PE20141482A1 (pt)
PH (2) PH12014501174A1 (pt)
PL (3) PL2785374T5 (pt)
PT (3) PT2785373T (pt)
RS (3) RS59893B1 (pt)
RU (1) RU2620936C2 (pt)
SI (3) SI2785374T1 (pt)
UA (1) UA118651C2 (pt)
WO (2) WO2013082327A1 (pt)
ZA (1) ZA201403804B (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3146727C (en) 2011-10-21 2023-10-31 Intervet International B.V. Recombinant non-pathogenic marek's disease virus constructs encoding infectious laryngotracheitis virus and newcastle disease virus antigens
PE20141482A1 (es) 2011-11-30 2014-11-08 Merial Ltd Vectores recombinantes de hvt que expresan antigenos de patogenos de aves y sus usos
EP2644702A1 (en) 2012-03-30 2013-10-02 Ceva Sante Animale Multivalent recombinant avian herpes virus and vaccine for immunizing avian species
AR097029A1 (es) * 2013-07-26 2016-02-17 Intervet Int Bv Aceleración de la respuesta inmune inducida por virus vectorial en aves, composición, uso, método para la vacunación y método para acelerar la respuesta inmune
EP2845904A1 (en) * 2013-09-06 2015-03-11 Ceva Sante Animale Recombinant Marek's disease viruses and uses thereof
AR103245A1 (es) * 2014-12-24 2017-04-26 Intervet Int Bv Vacuna vectorial basada en hvt (herpes virus de los pavos) frente a nd (enfermedad de newcastle) - ibd (enfermedad de gumboro) mejorada
US10537628B2 (en) 2015-08-10 2020-01-21 The Texas A&M University System Recombinant turkey herpesvirus vaccines and uses thereof
WO2017216287A1 (en) 2016-06-17 2017-12-21 Intervet International B.V. Recombinant non-pathogenic marek's disease virus constructs encoding infectious laryngotracheitis virus and infectious bursal disease virus antigens
JOP20190088A1 (ar) * 2016-10-21 2019-04-21 Us Agriculture نواقل مؤتلفة للتعبير عن مولدات مضاد فيروس انفلونزا الطيور و استخداماتها
KR102617503B1 (ko) * 2016-12-14 2023-12-29 뵈링거 잉겔하임 애니멀 헬스 유에스에이 인코포레이티드 조류 병원체의 다중 항원을 발현하는 재조합 hvt 벡터 및 그를 포함하는 백신
CN106701693A (zh) * 2017-01-19 2017-05-24 北京邦卓生物科技有限公司 表达血清ⅰ型马立克氏病病毒gb基因的重组火鸡疱疹病毒的构建及其应用
CN106929483B (zh) * 2017-01-19 2020-09-25 北京邦卓生物科技有限公司 表达鸡新城疫病毒f基因的重组火鸡疱疹病毒的构建及其应用
EP3391903B1 (en) * 2017-04-21 2022-02-23 The Pirbright Institute Recombinant gallid herpesvirus 3 vaccines encoding heterologous avian pathogen antigens
CN107099513B (zh) * 2017-06-22 2020-07-14 北京邦卓生物科技有限公司 一种共表达ndv hn和ibdv vp2基因的hvt的构建及其应用
CN107254450A (zh) * 2017-07-20 2017-10-17 扬州大学 克服鸡新城疫母源抗体影响的嵌合新城疫病毒疫苗载体候选株及构建方法
CN107603958A (zh) * 2017-09-29 2018-01-19 天津农学院 融合表达TM‑1基因和gD基因重组腺病毒的构建方法及重组腺病毒和应用
EP3694987A1 (en) * 2017-10-12 2020-08-19 Intervet International B.V. Recombinant non-pathogenic marek's disease virus constructs encoding multiple heterologous antigens
EP3727431A1 (en) 2017-12-20 2020-10-28 Intervet International B.V. Improved diluent for cell-associated alphaherpesvirus vaccine
CN108543067A (zh) * 2017-12-25 2018-09-18 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） 共表达h5亚型禽流感ha蛋白和传染性法氏囊vp2蛋白的重组火鸡疱疹病毒疫苗株
WO2019147869A2 (en) * 2018-01-24 2019-08-01 Virogin Biotech Canada Ltd Recombinant viral vaccines
CN109468315B (zh) * 2018-12-07 2021-09-07 袁隆平农业高科技股份有限公司 水稻耐淹基因Sub1共显性分子标记及应用
CN113226363A (zh) 2018-12-21 2021-08-06 法国诗华大药厂 含有多个外来基因的重组禽疱疹病毒
US11464849B2 (en) * 2019-09-11 2022-10-11 Zoetis Services Llc Recombinant herpesvirus of turkey vectors expressing antigens of avian pathogens and uses thereof
CN110872578B (zh) * 2019-11-29 2022-09-16 扬州优邦生物药品有限公司 一株变异株传染性法氏囊病毒、亚单位疫苗及其制备方法和应用
US11299517B2 (en) * 2020-04-15 2022-04-12 The United States Of America, As Represented By The Secretary Of Agriculture Recombinant vaccine against Marek's disease and Newcastle disease
MA58717A1 (fr) 2020-06-17 2023-06-28 Boehringer Ingelheim Vetmedica Gmbh Vecteurs hvt recombinants exprimant l'hémagglutinine de la grippe et compositions immunogènes, et leur fabrication et leurs utilisations
CN112206317B (zh) * 2020-10-12 2023-09-22 浙江省淡水水产研究所 一种草鱼出血病二价核酸菌蜕疫苗的制备方法
MX2023004358A (es) 2020-10-15 2023-07-25 Ceva Sante Animale Hvt recombinante y usos de este.
CN114317827B (zh) * 2022-01-07 2023-03-24 河南省农业科学院 一种鉴别不同血清型马立克病病毒感染与免疫的多重pcr引物、方法及应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4708871A (en) 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
EP0256092B1 (en) 1986-01-27 1998-04-08 Syntro Corporation Attenuated herpesviruses, herpesviruses which include foreign dna encoding an amino acid sequence and vaccine containing same
JP2779447B2 (ja) 1988-03-20 1998-07-23 財団法人阪大微生物病研究会 弱毒マレック病ウイルス・ベクターを用いる組換え遺伝子作成法、及び該ウイルスの組換え体
EP0431668B1 (en) 1989-12-04 1995-02-15 Akzo Nobel N.V. Recombinant herpesvirus of turkeys and live vector vaccines derived thereof
EP0575491B1 (en) 1991-03-07 2003-08-13 Virogenetics Corporation Genetically engineered vaccine strain
BE1004877A3 (fr) 1991-05-27 1993-02-16 Solvay Virus de l'avipox recombinant, culture de cellules infectees par ce virus et vaccins pour la volaille derives de ce virus.
US6183753B1 (en) 1994-08-09 2001-02-06 Schering-Plough Veterinary Corp. Recombinant chimeric virus and uses thereof
US5853733A (en) 1993-02-26 1998-12-29 Syntro Corporation Recombinant herpesvirus of turkeys and uses thereof
FR2719056B1 (fr) 1994-04-20 1996-09-06 Rhone Merieux Herpesvirus transformés pour exprimer gD in vitro.
PT776361E (pt) * 1994-08-09 2007-04-30 Schering Plough Ltd Herpesvírus recombinantes de perus e suas utilizações
RU2059414C1 (ru) * 1994-12-09 1996-05-10 Государственная Курская биофабрика - Фирма "БИОК" Поливалентная вакцина для профилактики болезни марека и способ ее изготовления
FR2728795B1 (fr) * 1994-12-30 1997-03-21 Rhone Merieux Vaccin vivant recombinant aviaire, utilisant comme vecteur un virus herpes aviaire
JPH104956A (ja) * 1996-06-21 1998-01-13 Univ Michigan State マレク病ワクチン製造のための維持可能な細胞株の改良
FR2751225B1 (fr) * 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique aviaire
EP1537877A3 (en) 1996-10-11 2005-08-03 The Regents Of The University Of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
US5980912A (en) 1997-03-25 1999-11-09 Zonagen, Inc. Chitosan induced immunopotentiation
EP1026246B1 (en) * 1997-10-03 2006-11-29 Zeon Corporation Avian infectious herpesvirus recombinants and recombinant vaccines prepared with the use of the same
EP0974660A1 (en) 1998-06-19 2000-01-26 Stichting Instituut voor Dierhouderij en Diergezondheid (ID-DLO) Newcastle disease virus infectious clones, vaccines and diagnostic assays
US6299882B1 (en) 1999-04-09 2001-10-09 Schering Corporation UL54.5 of Marek's disease virus (MDV)
KR100354972B1 (ko) 2000-04-11 2002-10-05 대한민국 닭전염성기관지염 바이러스 ｓ1 단백질을 발현하는유전자재조합 마렉바이러스 및 그의 제조방법
US6764684B2 (en) * 2001-09-28 2004-07-20 Zeon Corporation Avian herpesvirus-based recombinant infectious bursal disease vaccine
US6866852B2 (en) * 2002-01-31 2005-03-15 Zeon Corporation Recombinant herpesvirus of turkeys and use thereof
KR100801180B1 (ko) * 2006-09-26 2008-02-05 주식회사 고려비엔피 약독화된 재조합 뉴캐슬병 바이러스 및 이를 함유하는뉴캐슬병 백신
EP2419132B1 (en) * 2009-04-15 2014-06-25 Ceva Sante Animale Recombinant avian herpes virus vectors and vaccine for immunizing waterfowl species
PE20141482A1 (es) 2011-11-30 2014-11-08 Merial Ltd Vectores recombinantes de hvt que expresan antigenos de patogenos de aves y sus usos

Also Published As

Publication number Publication date
WO2013082327A8 (en) 2014-07-03
SI2785374T1 (sl) 2019-04-30
PH12015502790A1 (en) 2017-07-10
EP2785373B1 (en) 2019-11-20
HRP20190525T8 (hr) 2023-01-20
WO2013082317A8 (en) 2014-07-10
RS59892B1 (sr) 2020-03-31
RS58610B1 (sr) 2019-05-31
LT2785374T (lt) 2019-04-25
PT3251691T (pt) 2020-01-28
RS59893B1 (sr) 2020-03-31
CN104159604A (zh) 2014-11-19
EP3251691A1 (en) 2017-12-06
EP2785373A1 (en) 2014-10-08
HUE047909T2 (hu) 2020-05-28
DK3251691T3 (da) 2020-02-10
HK1247832A1 (zh) 2018-10-05
MX2014006361A (es) 2015-03-05
HK1248566A1 (zh) 2018-10-19
JP2015500806A (ja) 2015-01-08
PT2785373T (pt) 2020-01-27
LT3251691T (lt) 2020-02-10
SI2785373T1 (sl) 2020-02-28
ZA201403804B (en) 2015-04-29
CY1121528T1 (el) 2020-05-29
CN104159604B (zh) 2016-08-24
PL2785374T5 (pl) 2023-01-09
IN2014CN04833A (pt) 2015-09-18
JP6149301B2 (ja) 2017-06-21
HK1200018A1 (en) 2015-07-31
ME03433B (me) 2020-01-20
DK2785373T3 (da) 2020-02-03
PH12015502790B1 (en) 2017-07-10
CN104159605A (zh) 2014-11-19
EP3572092A1 (en) 2019-11-27
MX361893B (es) 2018-12-18
ES2719409T3 (es) 2019-07-10
RU2014126375A (ru) 2016-01-27
PL2785373T3 (pl) 2020-06-01
ES2775218T3 (es) 2020-07-24
PH12014501174B1 (en) 2014-09-08
HRP20190525T4 (hr) 2023-01-20
ES2719409T5 (es) 2022-12-07
EP2785374B2 (en) 2022-08-17
EP3263130A1 (en) 2018-01-03
LT2785373T (lt) 2020-02-10
CA2857025C (en) 2021-08-03
EP2785374A2 (en) 2014-10-08
HRP20192215T1 (hr) 2020-02-21
MX365984B (es) 2019-06-21
RU2620936C2 (ru) 2017-05-30
CN104159605B (zh) 2019-04-19
WO2013082317A3 (en) 2013-08-15
SI3251691T1 (sl) 2020-02-28
PL2785374T3 (pl) 2019-07-31
PE20141482A1 (es) 2014-11-08
PH12014501174A1 (en) 2014-09-08
AR089039A1 (es) 2014-07-23
HUE042471T2 (hu) 2019-07-29
KR20140097515A (ko) 2014-08-06
HRP20190525T1 (hr) 2019-05-03
EP3251691B1 (en) 2019-11-20
HK1197175A1 (en) 2015-01-09
CO7061033A2 (es) 2014-09-19
EP3578199A1 (en) 2019-12-11
CA2857025A1 (en) 2013-06-06
WO2013082327A1 (en) 2013-06-06
WO2013082317A2 (en) 2013-06-06
ES2785045T3 (es) 2020-10-05
PL3251691T3 (pl) 2020-06-01
CN105920598A (zh) 2016-09-07
BR112014013276B1 (pt) 2021-07-27
UA118651C2 (uk) 2019-02-25
AR090401A1 (es) 2014-11-12
EP4112073A1 (en) 2023-01-04
HRP20192241T1 (hr) 2020-03-06
PT2785374T (pt) 2019-05-09
MX2014006360A (es) 2015-03-05
KR102013135B1 (ko) 2019-08-22
CY1122872T1 (el) 2021-05-05
DK2785374T3 (en) 2019-04-08
EP2785374B1 (en) 2019-01-09
HUE047724T2 (hu) 2020-05-28
CY1124618T1 (el) 2022-03-24

Similar Documents

Publication Publication Date Title
BR112014013276A2 (pt) vetores hvt recombinantes expressando antígenos de patógenos aviários e usos dos mesmos
CO2019006820A2 (es) Vectores recombinantes de hvt que expresan múltiples antígenos de patógenos de aves y sus usos
BR112017001310A2 (pt) coronavírus
BR112017008266A2 (pt) partículas semelhantes a vírus modificadas de cmv
BR112013022397A2 (pt) vacinas combinadas com doses menores de antígeno e/ou adjuvante
CL2016000358A1 (es) Vacuna para adenovirus aviar
TW201613558A (en) Novel vaccine compositions for porcine epidemic diarrhea virus and porcine deltacoronavirus
BR112017020175A2 (pt) composições adjuvantes e métodos relacionados
CL2019003805A1 (es) Composiciones inmunógenas de senecavirus a y métodos de éstas.
PH12017501370A1 (en) Bivalent swine influenza virus vaccine
EA201391515A1 (ru) Инактивированная вакцина вируса денге
PH12019500854A1 (en) Recombinant vectors expressing antigens of avian influenza virus and uses thereof
MX2016016746A (es) Composiciones de vacuna con adyuvante dual, preparacion y usos.
BR112017003462A2 (pt) coronavírus bovino atenuado, vacina, e, método de vacinação de um bovino.
BR112018075440A2 (pt) composições e métodos para prevenir e tratar a infecção por zika vírus
BR112018076234A2 (pt) vacina contra o vírus da bronquite infecciosa
BR112017028212A2 (pt) vacinação concomitante contra dengue e febre amarela
BR112015032388A2 (pt) métodos e composições para as vacinas contra o vírus da dengue
BR112022004488A2 (pt) Herpesvírus recombinante de vetores de peru que expressam antígenos de patógenos aviários e seus usos
BR112018074910A2 (pt) composição imunológica, e, método de indução de uma resposta imunológica contra o vírus da influenza equina em um sujeito
PH12017501100B1 (en) Recombinant swinepox virus and vaccines
AR106501A1 (es) Adyuvante y composición de vacuna que lo contiene
BR112017004008A2 (pt) polipeptídeo recombinante, sequência de ácido nucleico, célula hospedeira, bionanopartícula, métodos para produção de uma bionanopartícula e para tratamento ou prevenção do vírus da dengue, e, vacina.
BR112021016182A2 (pt) Composição imunológica multivalente, e, método para induzir uma resposta imune contra uma pluralidade de vírus da influenza equina
BR112017010883A2 (pt) composições adjuvantes e métodos relacionados

Legal Events

Date Code Title Description
B25C Requirement related to requested transfer of rights

Owner name: MERIAL LIMITED (US)

B25A Requested transfer of rights approved

Owner name: MERIAL, INC. (US)

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/11/2012, OBSERVADAS AS CONDICOES LEGAIS.

B25A Requested transfer of rights approved

Owner name: BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC. (US)